Ara
Toplam kayıt 35, listelenen: 31-35
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
(Taylor & Francis Ltd, 2023)
AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ...
Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye
(2024)
According to current evidence, testing for germline BRCA pathogenic variants in newly diagnosed breast cancer (BC) patients has the potential to reduce the burden of the disease through targeted therapies and secondary ...
Investigating the roles of micrornas / lncrnas in characterizing breast cancer subtypes and prognosis
(2023)
Molecular subtyping is a method of separating tumor clusters in a cancer type with common features according to molecular data and classification models. Genome datasets are taken from many different people and some genetic ...
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
(2024)
Loss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. ...
Smart polymeric nanocarriers for miRNA delivery against triple negative breast cancer
(2024)
The most typical malignancy in women is breast cancer. This translates to almost 2.3 million women who have been diagnosed with the illness, which, according to the World Health Organization (WHO), resulted in more than ...